Detalhe da pesquisa
1.
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Rheumatology (Oxford)
; 60(5): 2277-2287, 2021 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33230526
2.
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Rheumatology (Oxford)
; 58(12): 2193-2202, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31184752
3.
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Arthritis Res Ther
; 21(1): 281, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31831079
4.
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
MAbs
; 10(6): 934-943, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010481